CNR1 and cancer: That is, it is a consensus that the eCBNs and related cannabinoid receptor agonists impact a multitude of cancer-related signalling pathways through the activation of both the CB1 and CB2 receptors, particularly the pathways associated with anti-proliferative and pro-apoptotic effects [27].